Back to Cell Types

NCI-H1755Homo sapiens (Human)Cancer cell line

Also known as: NCIH1755, H-1755, H1755

🤖 AI SummaryBased on 10 publications

Quick Overview

Human lung cancer cell line with potential for drug sensitivity studies.

Detailed Summary

The NCI-H1755 cell line is a human lung cancer cell line derived from a mesothelioma tumor. It is utilized in research for understanding cancer biology and drug sensitivity. Studies have shown that this cell line exhibits specific genetic and molecular characteristics that may influence its response to therapeutic agents. The cell line is part of the Cancer Cell Line Encyclopedia (CCLE) and has been used in various genomic and pharmacological studies to identify potential targets for cancer treatment. Its genetic profile includes mutations and expression patterns that are relevant to lung cancer research, making it a valuable resource for preclinical studies.

Research Applications

Cancer biology researchDrug sensitivity studiesGenomic and pharmacological profiling

Key Characteristics

Mutations in RB-related genesExpression of RB family proteinsPotential for targeted therapy research

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1492
Species	Homo sapiens (Human)
Tissue Source	Liver[UBERON:UBERON_0002107]

Donor Information

Age	65
Age Category	Adult
Sex	Female
Race	caucasian

Disease Information

Disease	Lung adenocarcinoma
Lineage	Lung
Subtype	Lung Adenocarcinoma
OncoTree Code	LUAD

DepMap Information

Source Type	ATCC
Source ID	ACH-000282_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Cys242Phe (c.725G>T)	Unspecified	-	PubMed=1394225
MutationSimple	BRAF	p.Gly469Ala (c.1406G>C)	Unspecified	-	PubMed=24576830, PubMed=21725359

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

12

D13S317

10,12

D16S539

11,12

D18S51

14,15

D19S433

12,13

D21S11

31

D2S1338

16,20

D3S1358

16

D5S818

11,12

D7S820

12

D8S1179

8,15

FGA

20,25

Penta D

8

Penta E

12

TH01

7

TPOX

8

vWA

18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Label-free quantitative proteomics and N-terminal analysis of human metastatic lung cancer cells.

Min H., Han D.-H., Kim Y., Cho J.Y., Jin J., Kim Y.

Mol. Cells 37:457-466(2014).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Mutations of the BRAF gene in human cancer.";

Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Nature 417:949-954(2002).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).